PMID- 36856834
OWN - NLM
STAT- MEDLINE
DCOM- 20230615
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 72
IP  - 7
DP  - 2023 Jul
TI  - Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and 
      lenvatinib in patients with advanced biliary tract carcinoma: a real-world study.
PG  - 2197-2204
LID - 10.1007/s00262-023-03399-2 [doi]
AB  - BACKGROUND: Radiotherapy (RT) may function synergistically with immunotherapy and 
      targeted agents (TA). This study aimed to assess the effectiveness and safety of 
      RT combined with programmed death-1 (PD-1) inhibitors and lenvatinib in patients 
      with relapsed or refractory advanced biliary tract carcinoma (BTC). METHODS: This 
      retrospective study included patients with relapsed or refractory advanced BTC 
      who received RT combined with PD-1 inhibitors and lenvatinib at the Peking Union 
      Medical College Hospital (PUMCH). Overall survival (OS), progression-free 
      survival (PFS), objective response rate (ORR), disease control rate (DCR), and 
      safety were evaluated. RESULTS: Thirty-one patients who received RT combined with 
      PD-1 inhibitors and lenvatinib as a second- or later-line therapy were analyzed. 
      RT sites were mainly distributed in the liver lesions (64.5%) and lymph nodes 
      (58.1%). The ORR and DCR were 32.3% (10/31; 95% CI: 14.8-49.7) and 87.1% (27/31; 
      95% CI: 74.6-99.6), respectively. The median PFS (mPFS) and median OS (mOS) were 
      7.9 (95% CI: 7.1-8.7) and 11.7 (95% CI: 8.3-15.0) months, respectively. Subgroup 
      analyses of this cohort included 12 and 19 patients who received concurrent and 
      salvage (> 6 weeks after commencing PD-1 inhibitor therapy) RT, respectively. The 
      salvage RT group had higher mOS (11.7 vs. 10.5; p = 0.75) and mPFS (7.9 vs. 6.9; 
      p = 0.85) than the concurrent RT group; however, statistical significance was not 
      reached. All patients experienced any-grade adverse events (AEs), and excessive 
      PD-1 inhibitors or RT toxicity were not observed. CONCLUSIONS: RT, PD-1 
      inhibitors, and lenvatinib may be safely combined and have antitumor 
      effectiveness in patients with advanced BTC.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Wang, Yunchao
AU  - Wang Y
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Yang, Xiaobo
AU  - Yang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Wang, Yanyu
AU  - Wang Y
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Xue, Jingnan
AU  - Xue J
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Zhang, Nan
AU  - Zhang N
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Yang, Xu
AU  - Yang X
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Cong, Ning
AU  - Cong N
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Zhang, Junwei
AU  - Zhang J
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Zhu, Chengpei
AU  - Zhu C
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Zhang, Longhao
AU  - Zhang L
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China.
FAU - Hou, Xiaorong
AU  - Hou X
AD  - Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China. hxr_pumch@163.com.
FAU - Zhao, Haitao
AU  - Zhao H
AD  - Department of Liver Surgery, Peking Union Medical College Hospital, Chinese 
      Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), No. 
      1, Shuaifuyuan, Dongcheng District, Beijing, China. zhaoht@pumch.cn.
LA  - eng
GR  - 2021-1-I2M-003 and 2021-I2M-1-061/CAMS Innovation Fund for Medical Sciences 
      (CIFMS)/
GR  - Y-MSDZD2021-0213/CSCO-MSD Cancer Research Fund/
GR  - Y-HR2019-0239, Y-HR2020MS-0415, Y-HR2020QN-0414/CSCO-hengrui Cancer Research 
      Fund/
PT  - Journal Article
DEP - 20230301
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - J27WDC343N (Mesothelin)
SB  - IM
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - Retrospective Studies
MH  - *Bile Duct Neoplasms
MH  - *Carcinoma
MH  - *Gastrointestinal Neoplasms
MH  - Mesothelin
MH  - *Biliary Tract
PMC - PMC10992455
OTO - NOTNLM
OT  - Advanced biliary tract cancer
OT  - Concurrent radiotherapy
OT  - Lenvatinib
OT  - PD-1 inhibitors
OT  - Salvage radiotherapy
COIS- The authors have no conflicts of interest to declare.
EDAT- 2023/03/02 06:00
MHDA- 2023/06/15 06:41
PMCR- 2023/03/01
CRDT- 2023/03/01 11:15
PHST- 2022/09/11 00:00 [received]
PHST- 2023/02/05 00:00 [accepted]
PHST- 2023/06/15 06:41 [medline]
PHST- 2023/03/02 06:00 [pubmed]
PHST- 2023/03/01 11:15 [entrez]
PHST- 2023/03/01 00:00 [pmc-release]
AID - 10.1007/s00262-023-03399-2 [pii]
AID - 3399 [pii]
AID - 10.1007/s00262-023-03399-2 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2023 Jul;72(7):2197-2204. doi: 
      10.1007/s00262-023-03399-2. Epub 2023 Mar 1.